Biosynth Names Matt Gunnison as CEO, Kieran Murphy Appointed as Chairman
Biosynth, a global supplier of critical raw materials for life sciences, has announced key leadership changes. Matt Gunnison, CEO of Gamma Biosciences, has been appointed as the new CEO, succeeding Urs Spitz, who will remain on the Board. Kieran Murphy, former President of GE Healthcare, has been named Chairman. Gunnison brings nearly two decades of healthcare and life sciences experience, while Murphy contributes extensive corporate leadership background. Additionally, Eric Simpson, previously VP at Gamma Biosciences, joins as Head of Corporate Development.
Biosynth, fornitore globale di materie prime critiche per le scienze della vita, ha annunciato importanti cambiamenti nella leadership. Matt Gunnison, CEO di Gamma Biosciences, è stato nominato nuovo CEO, succedendo a Urs Spitz, che rimarrà nel Consiglio. Kieran Murphy, ex Presidente di GE Healthcare, è stato nominato Presidente. Gunnison porta quasi due decenni di esperienza nel settore sanitario e delle scienze della vita, mentre Murphy contribuisce con una vasta esperienza nella leadership aziendale. Inoltre, Eric Simpson, precedentemente VP di Gamma Biosciences, si unisce come Responsabile dello Sviluppo Aziendale.
Biosynth, proveedor global de materias primas críticas para las ciencias de la vida, ha anunciado cambios clave en la dirección. Matt Gunnison, CEO de Gamma Biosciences, ha sido nombrado nuevo CEO, sucediendo a Urs Spitz, quien permanecerá en la Junta. Kieran Murphy, ex Presidente de GE Healthcare, ha sido nombrado Presidente. Gunnison aporta casi dos décadas de experiencia en atención médica y ciencias de la vida, mientras que Murphy aporta una extensa trayectoria en liderazgo corporativo. Además, Eric Simpson, anteriormente VP en Gamma Biosciences, se une como Jefe de Desarrollo Corporativo.
Biosynth는 생명 과학을 위한 중요한 원자재의 글로벌 공급업체로, 주요 리더십 변화를 발표했습니다. Matt Gunnison은 Gamma Biosciences의 CEO로 새로 임명되었으며, Urs Spitz는 이사회에 남게 됩니다. Kieran Murphy, 전 GE Healthcare 회장이 의장으로 임명되었습니다. Gunnison은 의료 및 생명 과학 분야에서 거의 20년의 경험을 보유하고 있으며, Murphy는 폭넓은 기업 리더십 배경을 제공합니다. 또한, Eric Simpson, 이전 Gamma Biosciences의 VP가 기업 개발 책임자로 합류합니다.
Biosynth, fournisseur mondial de matières premières essentielles pour les sciences de la vie, a annoncé d'importants changements de direction. Matt Gunnison, PDG de Gamma Biosciences, a été nommé nouveau PDG, succédant à Urs Spitz, qui restera au conseil d'administration. Kieran Murphy, ancien président de GE Healthcare, a été nommé président. Gunnison apporte près de deux décennies d'expérience dans le secteur de la santé et des sciences de la vie, tandis que Murphy contribue avec une vaste expérience en leadership d'entreprise. De plus, Eric Simpson, ancien VP de Gamma Biosciences, rejoint l'équipe en tant que responsable du développement des affaires.
Biosynth, ein globaler Anbieter kritischer Rohstoffe für die Lebenswissenschaften, hat wichtige Veränderungen im Management angekündigt. Matt Gunnison, CEO von Gamma Biosciences, wurde zum neuen CEO ernannt und folgt auf Urs Spitz, der im Vorstand bleiben wird. Kieran Murphy, ehemaliger Präsident von GE Healthcare, wurde zum Vorsitzenden ernannt. Gunnison bringt fast zwei Jahrzehnte Erfahrung im Gesundheitswesen und in den Lebenswissenschaften mit, während Murphy umfangreiche Erfahrungen in der Unternehmensführung einbringt. Außerdem tritt Eric Simpson, zuvor VP bei Gamma Biosciences, als Leiter der Unternehmensentwicklung bei.
- Appointment of experienced leadership with strong industry background
- Former CEO remains on Board ensuring continuity
- Strategic alignment with KKR, a major investment firm
- Previous CEO achieved notable growth during tenure
- None.
STAAD,
Matt Gunnison will succeed Urs Spitz, under whose guidance Biosynth has achieved remarkable growth and strengthened its position in the life sciences sector. Urs Spitz will remain a member of the Board of Directors.
“We are grateful to Urs for his significant contributions in shaping Biosynth into the innovative and thriving company it is today. We are now excited to welcome Matt as CEO, whose vision and extensive experience will be pivotal in leading the company through its next chapter,” said Kugan Sathiyanandarajah, Partner at KKR and Head of
“I am thrilled to join Biosynth at such an exciting time in its journey. The company has built a strong foundation under Urs’s leadership, and I look forward to working with the talented team to further accelerate our growth and innovation. Together, we will continue to deliver critical raw materials and services that drive advancements in the life sciences and make a real impact on global health outcomes,” said Matt Gunnison.
“It’s a privilege to be appointed Chairman of Biosynth. I am excited to work alongside Matt and the entire team as we chart the course for the company’s continued growth. Biosynth is at the forefront of innovation in the life sciences industry, and I am confident we have the right leadership and vision to drive our success forward,” said Kieran Murphy.
“I’m immensely proud of what Biosynth has accomplished. I would like to congratulate Matt and Kieran on their new roles and wish them, along with the whole Biosynth team, great success in the years ahead. I look forward to continuing to support them in my role on the Board as they lead Biosynth into this new chapter,” said Urs Spitz.
Matt currently serves as CEO of Gamma Biosciences, a life sciences investment platform that he co-founded with leading global investment firm KKR. He brings nearly two decades of experience in the healthcare and life sciences industries. At Gamma, Matt oversaw the acquisition and management of a portfolio of growth stage businesses serving the biopharmaceutical manufacturing industry. Prior to Gamma, he served in various positions at GE Healthcare, most recently as head of corporate development for the
Kieran currently serves as a senior advisor to KKR and will transition to Biosynth from Gamma Biosciences, where he has served as Chairman since 2022. He brings decades of corporate leadership and board experience in healthcare and life sciences, including as former President and CEO of GE Healthcare and GE Healthcare Life Sciences.
Joining Matt and Kieran, as Head of Corporate Development for Biosynth, is Eric Simpson, previously Vice President at Gamma Biosciences.
About Biosynth
Biosynth is a supplier of critical materials, securing life science supply chains with global research, manufacturing, and distribution facilities. Supplying the pharmaceutical and diagnostic sectors; where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. With an unrivaled research product portfolio of over a million products and end-to-end manufacturing services, Biosynth’s expertise and capability runs across Complex Chemicals, Peptides, and Key Biologics, all from one trusted partner. Headquartered in Staad,
About KKR
KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.
About Ampersand
Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with
View source version on businesswire.com: https://www.businesswire.com/news/home/20241106589561/en/
Biosynth
Alannah Wheeler
+44 7984 525560 marketing@biosynth.com
KKR
FGS Global
Alastair Elwen/ Jack Shelley
+44 20 7251 3801/ +44 7917 886 576 KKR-Lon@FGSGlobal.com
Ampersand
Kathleen Toomey kpt@ampersandcapital.com
Source: Biosynth
FAQ
Who is the new CEO of Biosynth in 2024?
What is Matt Gunnison's background before joining Biosynth?
Who replaced Urs Spitz as Biosynth's CEO?
Who is the new Chairman of Biosynth?
